In the last trading session, 7,263,068 shares of the Cellectar Biosciences, Inc.(NASDAQ:CLRB) were traded, and its beta was 1.68. Most recently the company’s share price was $2.5, and it changed around $0.04 or 0.02% from the last close, which brings the market valuation of the company to $113.62 Million. CLRB currently trades at a discount to its 52-week high of $2.98, offering almost -19.2% off that amount. The share price’s 52-week low was $1.01, which indicates that the current value has risen by an impressive 59.6% since then. We note from Cellectar Biosciences, Inc.’s average daily trading volume that its 10-day average is 4Million shares, with the 3-month average coming to 2.95 Million.

Get the hottest stocks to trade every day before the market opens 100% free. Click here now.

Cellectar Biosciences, Inc. stock received a consensus recommendation rating of Buy, based on a mean score of 1.7. If we narrow it down even further, the data shows that none out of 5 analysts rate the stock as a Sell; another but none rate it as Overweight. Among the rest, no body recommended CLRB as a Hold, whereas 5 deemed it a Buy, and no one rated it as Underweight. Cellectar Biosciences, Inc. is expected to report earnings per share of -$0.15 for the current quarter.

Cellectar Biosciences, Inc. (NASDAQ:CLRB): Trading Information

Instantly CLRB has showed a green trend with a performance of 1.63% at the end of last trading. The performance over the last five days has remained in the green territory. The rise to weekly highs of $2.67- on Friday, Feb 19 increased the stock’s daily price by 6.37%. The company’s shares are currently up 0.2% year-to-date, but still up 0.0081 over the last five days. On the other hand, Cellectar Biosciences, Inc. (NASDAQ:CLRB) is 0.28% up in the 30-day period. We can see from the shorts that 2.22 Million shares have been sold at a short interest cover period of 0.75 day(s).

The consensus price target as assigned by Wall Street analysts is $5.98, which translates to bears needing to increase their stock price by 139.2% from its current value. Analyst projections state that CLRB is forecast to be at a low of $3 and a high of $10. In order for the stock price to hit the forecast high, the stock would need to surge +300% from its current level, while the stock would need to crash 20% from its current level to reach the projected low.

Cellectar Biosciences, Inc. (CLRB) projections and forecasts

Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 59.8%. Cellectar Biosciences, Inc. earnings are expected to increase by 64.9% in 2021, but the outlook is negative 0% per year for the next five years.

Cellectar Biosciences, Inc. (NASDAQ:CLRB)’s Biggest Investors

Upon looking at major shareholders, it appears that insiders hold 13.66% of Cellectar Biosciences, Inc. shares, and 24.14% of them are in the hands of institutional investors. The stock currently has a share float of 27.96%. Cellectar Biosciences, Inc. stock is held by 29 institutions, with Sio Capital Management, LLC being the largest institutional investor. By Sep 29, 2020, it held 3% of the shares, which is about 1.36 Million shares worth $1.69 Million.

Boxer Capital, LLC, with 2.02% or 920Thousand shares worth $1.14 Million as of Sep 29, 2020, holds the second largest percentage of outstanding shares.


A Backdoor Way To Profit From Today’s Crypto Bull Market

Even if you’re not actively in crypto, you deserve to know what’s actually going on...

Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.

Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.

Sponsored


Get the hottest stocks to trade every day before the market opens 100% free. Click here now.

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

LEAVE A REPLY

Please enter your comment!
Please enter your name here